Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Intensified antibiotic treatment of tuberculosis meningitis.

Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R.

Expert Rev Clin Pharmacol. 2018 Nov 24:1-22. doi: 10.1080/17512433.2019.1552831. [Epub ahead of print]

PMID:
30474434
2.

The Global Landscape of Tuberculosis Therapeutics.

Tornheim JA, Dooley KE.

Annu Rev Med. 2019 Jan 27;70:105-120. doi: 10.1146/annurev-med-040717-051150. Epub 2018 Nov 7.

PMID:
30403551
3.

State-of-the-Art Review of HIV-TB Coinfection in Special Populations.

Weld ED, Dooley KE.

Clin Pharmacol Ther. 2018 Dec;104(6):1098-1109. doi: 10.1002/cpt.1221. Epub 2018 Oct 26.

PMID:
30137652
4.

Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Alfarisi O, Mave V, Gaikwad S, Sahasrabudhe T, Ramachandran G, Kumar H, Gupte N, Kulkarni V, Deshmukh S, Atre S, Raskar S, Lokhande R, Barthwal M, Kakrani A, Chon S, Gupta A, Golub JE, Dooley KE.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01383-18. doi: 10.1128/AAC.01383-18. Print 2018 Nov.

PMID:
30126955
5.

Challenges of TB and HIV co-treatment: updates and insights.

Tornheim JA, Dooley KE.

Curr Opin HIV AIDS. 2018 Nov;13(6):486-491. doi: 10.1097/COH.0000000000000495.

PMID:
30080683
6.

High-Dose Rifampin: Shall We Be Bolder?

Dooley KE.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):558-560. doi: 10.1164/rccm.201806-1140ED. No abstract available.

PMID:
29993257
7.

Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?

Dooley KE.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):833-834. doi: 10.5588/ijtld.18.0411. No abstract available.

PMID:
29991389
8.

The Global Neurological Burden of Tuberculosis.

Thakur K, Das M, Dooley KE, Gupta A.

Semin Neurol. 2018 Apr;38(2):226-237. doi: 10.1055/s-0038-1651500. Epub 2018 May 23. Review.

PMID:
29791949
9.

Preclinical tools for the evaluation of tuberculosis treatment regimens for children.

Tucker EW, Dooley KE.

Int J Tuberc Lung Dis. 2018 May 1;22(5):7-14. doi: 10.5588/ijtld.17.0354.

PMID:
29665948
10.

Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.

Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE.

Sci Transl Med. 2018 Apr 4;10(435). pii: eaai7786. doi: 10.1126/scitranslmed.aai7786.

PMID:
29618565
11.

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, Fehr J, Manabe YC, Castelnuovo B.

Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7. Review.

12.

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM.

Clin Pharmacokinet. 2018 Nov;57(11):1421-1433. doi: 10.1007/s40262-018-0642-9.

13.

HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression.

Warburton A, Redmond CJ, Dooley KE, Fu H, Gillison ML, Akagi K, Symer DE, Aladjem MI, McBride AA.

PLoS Genet. 2018 Jan 24;14(1):e1007179. doi: 10.1371/journal.pgen.1007179. eCollection 2018 Jan.

14.

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.

Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM.

Clin Pharmacol Ther. 2018 Oct;104(4):733-741. doi: 10.1002/cpt.987. Epub 2018 Feb 2.

15.

Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis.

Mave V, Kinikar A, Kagal A, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Gerona R, Wen A, Ramachandran G, Kumar H, Bacchetti P, Dooley KE, Gupte N, Gupta A, Gandhi M.

PLoS One. 2017 Dec 7;12(12):e0189101. doi: 10.1371/journal.pone.0189101. eCollection 2017.

16.

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01521-17. doi: 10.1128/AAC.01521-17. Print 2018 Feb.

17.

Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study.

Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, Hoffmann C, Dooley KE, Chaisson RE, Martinson N; TSHEPISO Study Team.

Clin Infect Dis. 2018 Mar 5;66(6):921-929. doi: 10.1093/cid/cix851.

PMID:
29028970
18.

Tuberculous meningitis.

Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE; Tuberculous Meningitis International Research Consortium.

Nat Rev Neurol. 2017 Oct;13(10):581-598. doi: 10.1038/nrneurol.2017.120. Epub 2017 Sep 8. Review.

PMID:
28884751
19.

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review.

PMID:
28803492
20.

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G.

J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152.

21.

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM.

Clin Transl Sci. 2017 Sep;10(5):366-379. doi: 10.1111/cts.12472. Epub 2017 May 31.

22.

Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.

McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE; Tshepiso Study Team.

J Antimicrob Chemother. 2017 Jul 1;72(7):2028-2034. doi: 10.1093/jac/dkx112.

23.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
24.

The time has come: sparing injectables in paediatric MDR-TB.

Weld ED, Garcia-Prats AJ, Furin JJ, Bailey TC, Hesseling AC, Dooley KE.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30078-4. doi: 10.1016/S2213-2600(17)30078-4. [Epub ahead of print] No abstract available.

PMID:
28344008
25.

Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.

Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA; Tuberculosis Trials Consortium.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02625-16. doi: 10.1128/AAC.02625-16. Print 2017 Jun.

26.

Tuberculosis Associated with HIV Infection.

Tornheim JA, Dooley KE.

Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TNMI7-0028-2016. Review.

PMID:
28233512
27.

Importance of Drug Pharmacokinetics at the Site of Action.

Rizk ML, Zou L, Savic RM, Dooley KE.

Clin Transl Sci. 2017 May;10(3):133-142. doi: 10.1111/cts.12448. Epub 2017 Feb 3. Review. No abstract available.

28.

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention.

Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2.

29.

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW.

PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.

30.

Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities.

McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR.

Int J Infect Dis. 2017 Mar;56:194-199. doi: 10.1016/j.ijid.2016.11.423. Epub 2016 Dec 9. Review.

31.

Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes.

Dooley KE, Warburton A, McBride AA.

MBio. 2016 Sep 13;7(5). pii: e01446-16. doi: 10.1128/mBio.01446-16.

32.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.

33.

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.

Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M.

Int J Tuberc Lung Dis. 2016 Jun;20(6):844-7. doi: 10.5588/ijtld.15.0882.

34.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

35.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M.

BMC Med. 2016 Mar 23;14:51. doi: 10.1186/s12916-016-0597-3.

36.

Challenges in the clinical assessment of novel tuberculosis drugs.

Dooley KE, Phillips PP, Nahid P, Hoelscher M.

Adv Drug Deliv Rev. 2016 Jul 1;102:116-22. doi: 10.1016/j.addr.2016.01.014. Epub 2016 Jan 28. Review.

37.

Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.

Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A.

Clin Infect Dis. 2016 Mar 15;62(6):761-769. doi: 10.1093/cid/civ991. Epub 2015 Dec 9.

38.

Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.

Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H, Dooley KE.

Antimicrob Agents Chemother. 2015 Dec 7;60(3):1234-41. doi: 10.1128/AAC.02051-15.

39.

Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.

Svensson EM, Acharya C, Clauson B, Dooley KE, Karlsson MO.

AAPS J. 2016 Jan;18(1):171-9.

40.

Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa.

Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, Haas DW, Dooley KE, Martinson NA, Chaisson RE.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):31-7. doi: 10.1097/QAI.0000000000000811.

41.

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE.

Clin Pharmacol Ther. 2015 Dec;98(6):622-9. doi: 10.1002/cpt.202. Epub 2015 Oct 22.

42.

Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment.

Srikrishna G, Gupta S, Dooley KE, Bishai WR.

Future Microbiol. 2015;10(8):1257-60. doi: 10.2217/FMB.15.56. Epub 2015 Jul 30. No abstract available.

43.

Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.

Garcia-Prats AJ, Draper HR, Thee S, Dooley KE, McIlleron HM, Seddon JA, Wiesner L, Castel S, Schaaf HS, Hesseling AC.

Antimicrob Agents Chemother. 2015 Oct;59(10):6073-9. doi: 10.1128/AAC.01404-15. Epub 2015 Jul 20.

44.

Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.

DeMarco VP, Ordonez AA, Klunk M, Prideaux B, Wang H, Zhuo Z, Tonge PJ, Dannals RF, Holt DP, Lee CK, Weinstein EA, Dartois V, Dooley KE, Jain SK.

Antimicrob Agents Chemother. 2015 Sep;59(9):5768-74. doi: 10.1128/AAC.01146-15. Epub 2015 Jul 13.

45.

Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team.

Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30.

46.

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.

Svensson EM, Murray S, Karlsson MO, Dooley KE.

J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21.

47.

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Erratum in: Am J Respir Crit Care Med. 2015 May 15;191(10):1210.

48.

Designing drug trials: considerations for pregnant women.

Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M.

Clin Infect Dis. 2014 Dec 15;59 Suppl 7:S437-44. doi: 10.1093/cid/ciu709.

49.

Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.

Parsons TL, Marzinke MA, Hoang T, Bliven-Sizemore E, Weiner M, Mac Kenzie WR, Dorman SE, Dooley KE.

Antimicrob Agents Chemother. 2014 Nov;58(11):6747-57. doi: 10.1128/AAC.03607-14. Epub 2014 Sep 2.

50.

Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.

Svensson EM, Dooley KE, Karlsson MO.

Antimicrob Agents Chemother. 2014 Nov;58(11):6406-12. doi: 10.1128/AAC.03246-14. Epub 2014 Aug 11.

Supplemental Content

Loading ...
Support Center